Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Phoenix Biotech Acquisiti...

    NASDAQ: PBAX · Real-Time Price · USD
    5.85
    0.37 (6.75%)
    At close: Feb 14, 2024, 8:56 PM

    Phoenix Biotech Acquisition Statistics

    Share Statistics

    Phoenix Biotech Acquisition has - shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 n/a

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 1,804

    FTD / Avg. Volume

    n/a
    		 22.33%

    Short Selling Information

    The latest short interest is 757, so 0.01% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 757

    Short % of Shares Out

    n/a
    		 0.01%

    Short % of Float

    n/a
    		 0.02%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -275.25 and the forward PE ratio is null. Phoenix Biotech Acquisition's PEG ratio is -1.6.

    PE Ratio

    n/a
    		 -275.25

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 721.25

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 74.45

    P/FCF Ratio

    n/a
    		 -168.27

    PEG Ratio

    n/a
    		 -1.6
    Financial Ratio History

    Enterprise Valuation

    Phoenix Biotech Acquisition has an Enterprise Value (EV) of 183.97M.

    EV / Sales

    n/a
    		 721.93

    EV / EBITDA

    n/a
    		 -32.04

    EV / EBIT

    n/a
    		 -168.43

    EV / FCF

    n/a
    		 -168.43

    Financial Position

    The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.26.

    Current Ratio

    n/a
    		 1.38

    Quick Ratio

    n/a
    		 1.38

    Debt / Equity

    n/a
    		 0.26

    Debt / EBITDA

    n/a
    		 -0.11

    Debt / FCF

    n/a
    		 -0.6

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is -27.05% and Return on Invested Capital is -21.41%.

    Return on Equity

    n/a
    		 -27.05%

    Return on Assets

    n/a
    		 -1.58%

    Return on Invested Capital

    n/a
    		 -21.41%

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 n/a

    Employee Count

    n/a
    		 undefined

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 599.16K

    Effective Tax Rate

    n/a
    		 -873.7%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is 0.04, so Phoenix Biotech Acquisition's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.04

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 10.38

    200-Day Moving Average

    n/a
    		 10.74

    Relative Strength Index (RSI)

    n/a
    		 29.6

    Average Volume (20 Days)

    n/a
    		 8,080

    Income Statement

    In the last 12 months, Phoenix Biotech Acquisition had revenue of 254.83K and earned -667.74K in profits. Earnings per share was -0.04.

    Revenue

    n/a
    		 254.83K

    Gross Profit

    n/a
    		 254.83K

    Operating Income

    n/a
    		 -68.58K

    Net Income

    n/a
    		 -667.74K

    EBITDA

    n/a
    		 -5.74M

    EBIT

    n/a
    		 n/a

    Earnings Per Share (EPS)

    n/a
    		 -0.04
    Full Income Statement

    Balance Sheet

    The company has 475.87K in cash and 650K in debt, giving a net cash position of -174.13K.

    Cash & Cash Equivalents

    n/a
    		 475.87K

    Total Debt

    n/a
    		 650K

    Net Cash

    n/a
    		 -174.13K

    Retained Earnings

    n/a
    		 -10.76M

    Total Assets

    n/a
    		 8.47M

    Working Capital

    n/a
    		 3.67M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -1.09M and capital expenditures 0, giving a free cash flow of -1.09M.

    Operating Cash Flow

    n/a
    		 -1.09M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -1.09M

    FCF Per Share

    n/a
    		 -0.06
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -26.91% and -262.03%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -26.91%

    Pretax Margin

    n/a
    		 -26.91%

    Profit Margin

    n/a
    		 -262.03%

    EBITDA Margin

    n/a
    		 -2253.38%

    EBIT Margin

    n/a
    		 -26.91%

    FCF Margin

    n/a
    		 -428.62%

    Dividends & Yields

    PBAX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -0.36%

    FCF Yield

    n/a
    		 -0.59%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for PBAX.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -0.74

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist